Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.
about
Update on clinical research and state of the art management of patients with advanced sarcomas and GISTGastrointestinal stromal tumors (GISTs): point mutations matter in management, a review.NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours.Updates on the management of gastrointestinal stromal tumors.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Gastrointestinal stromal tumors-diagnosis and management: a brief review.Randomized clinical trials in gastrointestinal stromal tumorsRegorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.Gastrointestinal tumors of the colon and rectumState-of-the art therapy for gastrointestinal stromal tumors.State of the Art in the Treatment of Gastrointestinal Stromal Tumors.Transcatheter arterial chemoembolization for gastrointestinal stromal tumors with liver metastases.Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach.Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs.Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study).Multidisciplinary treatment of gastrointestinal stromal tumors.Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.The role of surgery in the multidisciplinary management of patients with localized gastrointestinal stromal tumors.Regorafenib for treatment of advanced gastrointestinal stromal tumors.Trabectedin: novel insights in the treatment of advanced sarcoma.Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy.Treatments for gastrointestinal stromal tumors that are resistant to standard therapies.An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients.Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.Contrast-enhanced harmonic endoscopic ultrasound is able to discriminate benign submucosal lesions from gastrointestinal stromal tumors.Accomplishments in 2008 in the management of gastrointestinal stromal tumors.Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice
P2860
Q28073290-FCD2BF03-D713-4079-80BD-3E52804A4705Q33895608-349B9300-807D-429C-AC15-8553D45F3DDEQ33921067-F8856913-B1D9-4B4C-BFBA-6CBC24A31C66Q34141825-4FA3E8A7-8FDD-4DB6-A74D-CDD9B3A518DDQ34256921-2670EFA2-8C2C-48D6-A5F0-8D3677789CA0Q34645665-68C91CB8-A5DB-4D2C-BE71-D88593606AFDQ34986676-6DAA6058-0365-4F70-9D2A-8B6C60D9C6E6Q35188114-90B27894-8438-41D3-8410-DF51037119C2Q35519994-971BEB05-F903-47A1-9113-8C91237B90EFQ35850185-4C1F4B50-3448-488C-9535-3F70EC3BCE2AQ36156933-841EEF7E-17BD-488F-AF67-298B3966EE78Q36344557-C3254034-5E60-499A-84D7-1E93EE7EABF4Q36395393-D44E9A73-CA4E-430E-9D50-EEE6588A1B6CQ36491906-5DE304FB-FFAB-4F49-8A61-70496DB92D86Q36563238-4EFAA37E-A69B-439F-894E-5B07CC54D4B7Q37182155-EEB2B59B-C53C-4E6A-8CFC-BE759C803828Q37229787-777A0635-9186-41E0-BDF5-93217E25F817Q37342909-159574F2-B779-4171-9E8E-189D0B473B4CQ37954205-4043C819-8F10-49E9-B01E-954D2C37C9DEQ38048820-7144349E-88DE-4280-8DE8-52A39D4E6AF7Q38176966-E33A25A8-04B3-4623-B971-DD0ECFF2447AQ38206396-2F882CC0-DB3B-487D-ABB0-F953C11E44AEQ38262501-AC3EB211-D0E9-4C38-BC2C-038B65A22903Q38268165-C36A829A-907C-44B5-A041-86C5953C3141Q38869809-0C032824-6594-445B-96A4-6F2B38DF18C3Q38925022-70D322EC-16F5-491F-8A11-A35AD4CDB9C6Q39520779-EBE27771-A2C9-49C9-B187-C5C06C72EB20Q42287336-1CD080E2-EC8F-4CBE-98A0-A91A24490B14Q56979972-DE5A0523-B4BE-4581-9DE0-59182B76B883
P2860
Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Contrast of response to dacarb ...... ther advanced leiomyosarcomas.
@ast
Contrast of response to dacarb ...... ther advanced leiomyosarcomas.
@en
type
label
Contrast of response to dacarb ...... ther advanced leiomyosarcomas.
@ast
Contrast of response to dacarb ...... ther advanced leiomyosarcomas.
@en
prefLabel
Contrast of response to dacarb ...... ther advanced leiomyosarcomas.
@ast
Contrast of response to dacarb ...... ther advanced leiomyosarcomas.
@en
P2093
P2860
P356
P1433
P1476
Contrast of response to dacarb ...... ther advanced leiomyosarcomas.
@en
P2093
Jan C Buckner
John H Edmonson
Michelle R Mahoney
Randolph S Marks
P2860
P304
P356
10.1081/CNV-120002485
P577
2002-01-01T00:00:00Z